Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Arnd Nusch"'
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
Guy Jerusalem, Thomas E. Delea, Migule Martin, Michelino De Laurentiis, Arnd Nusch, J. Thaddeus Beck, Arlene Chan, Seock-Ah Im, Patrick Neven, Alexander Lonshteyn, David Chandiwana, Brad Lanoue, Peter A. Fasching
Publikováno v:
Clinical breast cancer. 22(4)
MONALEESA-3 demonstrated an overall survival (OS) benefit for ribociclib plus fulvestrant (R+F) in postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer (ABC). This study estimated quality-adjusted (QA) surviv
Autor:
Sina Grebhardt, Arnd Nusch, Richard A. Hansen, Ulrike Söling, Johanna Harde, Karin Potthoff, Norbert Marschner, Christoph Salat
Publikováno v:
Clinical Breast Cancer. 18:e1323-e1337
One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials ha